Bridging Clinical Gaps in B-Cell Lymphomas: Linking Novel Mechanisms to Advance New Treatment Strategies

/ Print /
| ShareMore
/ Text Size +
12/10/21 7:00 pm EDT
Virtual Webinar

Rapid updates in optimal personalized management of hematologic malignancies have necessitated increased awareness of emerging targets, such as BTK, BCL2, PI3K, and CD20. This has led to the development of novel treatment strategies in second-line and maintenance settings for patients with B-cell lymphomas, including follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL).

Learning Objectives

The learning objectives of this program are:

  • Identify diagnostic and prognostic biomarkers that guide treatment planning in MZL, FL, and MCL
  • Apply safety and efficacy data for emerging treatment options, including chemotherapy-free regimens, to clinical scenarios in MZL, FL, and MCL
  • Develop strategies to mitigate, monitor, and manage adverse events associated with therapeutic regimens used in the treatment of patients with MZL, FL, and MCL
  • Evaluate recently reported and ongoing clinical trials of novel agents and therapeutic combinations for patients with MZL, FL, and MCL

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with non-Hodgkin lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with non-Hodgkin lymphoma are also invited to attend.


Friday, December 10, 2021

Scientific Session: 7:00 PM – 10:00 PM Eastern Time

Live, Virtual Satellite Symposium


Program Chair

Jason Westin, MD, MS, FACP
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine
Director, Lymphoma Clinical Research Program Section
Chief, Aggressive Lymphoma
The University of Texas MD Anderson Cancer Center
Houston, TX